The following interactive courses are available for P.A.C.E. credit.  In order to receive your P.A.C.E. certificate, you must:

  • Complete the course material.
  • Take and pass a final exam. If you do not pass the exam, you must retake the course to attempt the exam again.
  • Complete the online evaluation.

New York Blood Center Enterprises is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program.

(eLearning courses are best viewed using Chrome as a browser.)

New eLearning Course Available! 

Author: Lynsi Rahorst, MHPE, MLS(ASCP)SBB

P.A.C.E. Contact Hours: 1.0

Level of Instruction: Basic

Objectives:

  • Describe the RHCE gene, including alleles encoding common phenotypes. 
  • List different applications for RHCE genotyping beyond the common alleles.
  • Discuss RHCE variant alleles, including how phenotypes and alloimmunization risk may be affected.
Innovative Blood Resources, a division of New York Blood Center Enterprises, regularly hosts local Technical Advisory Meetings (TAMs) that often contain an educational component.  This was recorded in December, 2023.

Individual Risk-Based Assessment, Directed Donations, & the Monocyte Monolayer Assay

Speakers: Jed Gorlin, MD, MBA & Maisee Her, SBB(ASCP)

P.A.C.E. Contact Hours: 1.0

Level of Instruction: Basic

Objectives:

  • Discuss individual risk assessment, including the process for implementation.
  • Define directed donation & explain criteria for requesting directed donations.
  • Describe the Monocyte Monolayer Assay (MMA) and discuss the use of the MMA in patient cases.

Authors: Lynsi Rahorst, MHPE, MLS(ASCP)SBBCM & Kay Stephens, MT(ASCP)SH

P.A.C.E. Contact Hours: 1.0

Level of Instruction: Intermediate

Objectives:

  • Describe characteristics of the ABO blood group system, including antigens, antibodies and genetics.
  • Identify and describe several causes of ABO discrepancies.
  • List techniques used to resolve ABO discrepancies and arrive at appropriate ABO interpretations based on laboratory results.

Author: Lynsi Rahorst, MHPE, MLS(ASCP)SBBCM

P.A.C.E. Contact Hours: 1.0

Level of Instruction: Intermediate

Objectives:

  • Define RHD allele and discuss the effect alleles have on the RhD protein expressed on RBCS.
  • Describe five categories of RHD alleles: conventional, null, alleles encoding weak D, alleles encoding partial D, DEL.
  • List different indications for RHD genotyping.

Author: Lynsi Rahorst, MHPE, MLS(ASCP)SBBCM

P.A.C.E. Contact Hours: 1.0

Level of Instruction: Intermediate

Objectives:

  • Describe different assays that are used in RH genotyping.
  • Identify notations for nucleotide changes in the gene, amino acid changes in the protein, and RH alleles detected on a genotype report.
  • Discuss predicted phenotypes associated with RH genotyping results.

Author: Kay Stephens, MLS(ASCP)SH

P.A.C.E. Contact Hours: 1.0

Level of Instruction: Basic

Objectives:

  • Explain the steps in the donation process for whole blood, apheresis red cells, and apheresis platelets.
  • Describe the manufacturing, testing, lot release, and labeling processes for blood components.
  • Discuss the role of the following blood center departments: Immunohematology Reference Laboratory, Genomics Laboratory, Distribution (Hospital Services), and Quality Assurance.

Other eLearning Courses Available

Author: Nancy Van Buren, MD & Kay Stephens, MT(ASCP)SH

P.A.C.E. Contact Hours: 1.0

Level of Instruction: Intermediate

Objectives:

  • Discuss the CBC National Healthcare Safety Network (NHSN) criteria for classifying adverse transfusion events.
  • Describe the NHSN case definitions of TRALI, TACO and TAD.
  • Evaluate the information presented in the case studies to identify the type of pulmonary adverse transfusion event and apply the appropriate CBC NHSN definition criteria. 

Author: Nancy Van Buren, MD & Kay Stephens, MT(ASCP)SH

P.A.C.E. Contact Hours: 1.0

Level of Instruction: Intermediate

Objectives:

  • Discuss the CDC National Healthcare Safety Network (NHSN) criteria for classifying adverse transfusion events.  
  • Describe the signs and symptoms of adverse transfusion events presented in case studies.
  • Evaluate the information presented in the case studies to identify the type of adverse transfusion event and apply the appropriate CDC NHSN case definition criteria. 

Author: Kay Stephens, MT(ASCP)SH

P.A.C.E. Contact Hours: 1.0

Level of Instruction: Intermediate

Course Objectives:

  • Identify the clinical presentations, causes, and subtypes of autoimmune hemolytic anemia.
  • Describe the role of the Direct Antiglobulin Test in the serologic evaluation of autoimmune hemolytic anemia.
  • Discuss treatment and transfusion management.

Authors: Nancy Van Buren, MD & Kay Stephens, MT(ASCP)SH

P.A.C.E. Contact Hours: 1.0

Level of Instruction: Intermediate

Course Objectives:

  • Explain the etiology of sickle cell disease and discuss the transfusion options and transfusion complications in this population.
  • Identify the American Society of Hematology (ASH) 2020 guidelines for transfusion support for sickle cell disease.
  • Discuss the role of genotyping and antigen-matched blood for patients with sickle cell disease in a chronic transfusion therapy program.

Author: Lynsi Rahorst, MHPE, MLS(ASCP)SBBCM & Kay Stephens, MT(ASCP)SH

P.A.C.E. Contact Hours: 1.0

Level of Instruction: Intermediate

Objectives:

  • Define characteristics of common blood group antigens and antibodies.
  • Determine the clinical significance of antibodies to common blood group antigens.
  • Select appropriate units for transfusion in case scenarios.

Author: Megan Dupont, MLS(ASCP)CMSBBCM

P.A.C.E. Contact Hours: 1.0

Level of Instruction: Intermediate

Objectives:

  • Discuss the strategies to reduce alloimmunization in chronically transfused patients.
  • Define RH variant alleles and describe how variants may impact patients.
  • Describe the investigation of a patient in which Rh antibody was produced despite selection of prophylactic matched red cells

Author: Nancy Van Buren, MD & Jed Gorlin, MD, MBA

P.A.C.E. Contact Hours: 0.5

Level of Instruction: Intermediate

Course Objectives:

  • Identify the reasons for the donor deferral criterion related to men who have sex with men (MSM) and women who have sex with MSM and describe how the ADVANCE study will inform the FDA’s decision to move towards individualized risk assessment of donors which fosters inclusivity and respect.
  • Explain why pre-exposure prophylaxis (PrEP) drugs impact donor deferral.
  • Discuss donor eligibility issues for gender non-conforming donors and describe Innovative Blood Resources approach to overcoming these challenges.